Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Norris Perne & French LLP MI

Norris Perne & French LLP MI grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 129,082 shares of the medical research company's stock after acquiring an additional 3,028 shares during the period. Charles River Laboratories International comprises approximately 1.5% of Norris Perne & French LLP MI's holdings, making the stock its 28th biggest holding. Norris Perne & French LLP MI owned about 0.26% of Charles River Laboratories International worth $19,429,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in CRL. Vanguard Group Inc. increased its holdings in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after purchasing an additional 60,497 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after buying an additional 335,658 shares during the period. Geode Capital Management LLC boosted its position in shares of Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after buying an additional 14,787 shares during the period. Ariel Investments LLC grew its stake in shares of Charles River Laboratories International by 18.9% in the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock valued at $197,029,000 after buying an additional 169,640 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Charles River Laboratories International by 17.1% in the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after buying an additional 151,159 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

CRL opened at $145.24 on Thursday. The company has a market capitalization of $7.13 billion, a P/E ratio of -223.44, a PEG ratio of 4.47 and a beta of 1.48. The company has a 50-day moving average of $129.86 and a 200-day moving average of $156.31. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the firm earned $2.27 earnings per share. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of analyst reports. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a report on Wednesday, May 14th. Mizuho dropped their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Barclays boosted their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.